Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry
出版年份 2017 全文链接
标题
Somatic MED12
Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry
作者
关键词
-
出版物
HUMAN MUTATION
Volume 38, Issue 3, Pages 269-274
出版商
Wiley
发表日期
2017-01-05
DOI
10.1002/humu.23157
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- MED12 Regulates HSC-Specific Enhancers Independently of Mediator Kinase Activity to Control Hematopoiesis
- (2016) Beatriz Aranda-Orgilles et al. Cell Stem Cell
- The rules and impact of nonsense-mediated mRNA decay in human cancers
- (2016) Rik G H Lindeboom et al. NATURE GENETICS
- Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL
- (2015) R. Guieze et al. BLOOD
- Med12 gain-of-function mutation causes leiomyomas and genomic instability
- (2015) Priya Mittal et al. JOURNAL OF CLINICAL INVESTIGATION
- Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors
- (2015) Andi K. Cani et al. MOLECULAR CANCER RESEARCH
- The Mediator complex: a central integrator of transcription
- (2015) Benjamin L. Allen et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia
- (2015) Kati Kämpjärvi et al. Oncotarget
- Macromolecular transport between the nucleus and the cytoplasm: Advances in mechanism and emerging links to disease
- (2014) Elizabeth J. Tran et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Mutations in Exon 1 Highlight the Role ofMED12in Uterine Leiomyomas
- (2014) Kati Kämpjärvi et al. HUMAN MUTATION
- Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia
- (2014) M Kontro et al. LEUKEMIA
- Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma
- (2014) Weng Khong Lim et al. NATURE GENETICS
- Uterine Leiomyoma-Linked MED12 Mutations Disrupt Mediator-Associated CDK Activity
- (2014) Mikko Turunen et al. Cell Reports
- Characterization of Uterine Leiomyomas by Whole-Genome Sequencing
- (2013) Miika Mehine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns
- (2012) A. Schuh et al. BLOOD
- Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer
- (2012) K Kämpjärvi et al. BRITISH JOURNAL OF CANCER
- MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
- (2012) Sidong Huang et al. CELL
- A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells
- (2012) Kyle J. Roux et al. JOURNAL OF CELL BIOLOGY
- Nuclear pore complex composition: a new regulator of tissue-specific and developmental functions
- (2012) Marcela Raices et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Whole Exome Sequencing in a Random Sample of North American Women with Leiomyomas Identifies MED12 Mutations in Majority of Uterine Leiomyomas
- (2012) Megan M. McGuire et al. PLoS One
- MED12 Alterations in Both Human Benign and Malignant Uterine Soft Tissue Tumors
- (2012) Gaëlle Pérot et al. PLoS One
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
- (2011) Lili Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanism of escape from nonsense-mediated mRNA decay of human -globin transcripts with nonsense mutations in the first exon
- (2011) G. Neu-Yilik et al. RNA
- MED12, the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas
- (2011) N. Makinen et al. SCIENCE
- Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling
- (2010) P. P. Rocha et al. DEVELOPMENT
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started